Global mRNA Therapeutics Market Insights Forecasts to 2030
- The mRNA Therapeutics Market Size was valued at USD 33.60 Billion in 2021.
- The Market Size is Growing at a CAGR of 2.2% from 2022 to 2030
- The Worldwide mRNA Therapeutics Market Size is expected to reach USD 38.15 Billion by 2030
- Europe is expected to Grow the fastest during the forecast period
Get more details on this report -
The Global mRNA Therapeutics Market Size is expected to reach USD 38.15 Billion by 2030, at a CAGR of 2.2% during the forecast period 2022 to 2030.
A single protein-coding gene serves as the foundation for protein synthesis in cells and is known as messenger ribonucleic acid (mRNA). The desired immunological characteristics are combined in mRNA vaccines and RNA interference (RNAi) treatments, which are created in labs utilising mammalian cells. Self-amplifying, non-replicating, in vivo self-replicating, and in vitro dendritic cell non-replicating mRNA are a few of the frequently used vaccine and treatment types. They are injected into the body to activate immunological sensors that recognise viruses and cause cell production of viral antigen proteins. As a result, the body's B- and T-cell responses are improved, which helps to strengthen immunity.
mRNA therapeutics market size is estimated to make significant growth across the world over the predicted timeframe due the rising cases of chronic diseases and infectious disease as well as different initiatives taken by the government for big projects. Moreover, the rising significance of COVID 19 vaccinations introduced by Moderna with Pfizer-BioNTech has resulted into the rise in the amount of protein expression vaccine treatments that are being tested in cancer clinical studies.
COVID 19 Impact mRNA Therapeutics Market
The year 2021 has witnessed a second highest amount of mRNA vaccination research and development activities with people who are suffering from cancer after COVID 19 studies which has expanded the market. The COVID 19 pandemic has impacted the market positively which has expanded the global mRNA therapeutics market. This has resulted into the increase the number of COVID 19 patients across the world and huge external investment for the development of messenger RNA created COVID 19 vaccinations. Apart from this, as mRNA vaccinations provide a strong defense against different types of COVID 19 health ailments, the demand of these vaccines has increased exponentially in various parts of the world.
Global mRNA Therapeutics Market Report Coverage
|Market Size in 2021:||USD 33.60 Billion|
|Forecast Period 2021-2030 CAGR:||2.2%|
|2030 Value Projection:||USD 38.15 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Application, By Type, By End-use, By Region, COVID-19 Impact Analysis|
|Companies Covered:||Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, TIBA Biotech|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Key Market Drivers
Increasing number of chronic and communicable diseases
Over a decade, the world has witnessed a significant increase in the number of long lasting and infectious diseases across the world. Leaving all the personal grooming and safety measures aside, the communicable and chronic diseases are increasing and spreading among people. The food and nourishment are the key determinants that will prevent from such type of diseases but declining nutritious content in food is the reason which is increasing prevalence of diseases. The common chronic diseases are cancers, diabetes, neurological disorders, osteoporosis, and cardiovascular problems. As per the report released by the WHO, cancel will hold more than 11 million deaths in 2021 across the world.
Increasing acceptance of mRNA vaccinations
The Market is driving due to the increasing number of rare conditions such as propionic metabolic acidosis, methylmalonic acidemia, glycogen illness, immunological disorders, metabolism, and phenylketonuria, as well as chronic health ailments like cancer, heart disease, CKD, pulmonary, and others. For instance, as per the Globocan, the world has witnessed millions of deaths due to cancer in the year 2020.
Key Market Challenges
Low production cost and safer administration
In the Market mRNA based COVID 19 are considered the appropriate option as compared to traditional vaccination methods as patients get recovered quickly which will contribute the growth of the products. However, the production and deliver of these vaccines should be affordable and simpler.
Key Market Opportunities
Using mRNA technology and creating mRNA biomarkers
The global demand for mRNA vaccines as well as RNAi treatments is estimated to increase over the forecast period owing the increasing number of chronic and infectious diseases. Additionally, the other factors which play significant roles in the expansion of the market are sensitivity of therapy, targeted specialization, as well as increased awareness of immunization. Bur the risk of failing in market studies in quantifying mRNA will hamper the expansion of market. In 2021, US mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture as part of a joint venture with Axcelead, Inc., and is now building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.
The prophylactic vaccines segment accounted the largest market share over the forecast period.
On the basis of type, the Global mRNA Therapeutics Market Size is segmented into prophylactic vccines, therapeutic vaccines, and therapeutic drugs. Among these, the prophylactic vaccines segment is dominating the market and is going to continue its dominance over the forecast period. As per the data given by Nature’s opinion, the prophylactic vaccines are the result of present research and development efforts having more than 50% of mRNA businesses with minimum one preventive vaccine in development. Other vaccines for disorders including influenza and respiratory syncytial virus also contribute to the category growth, but COVID-19 products currently account for the vast bulk of preventive vaccine revenues. Rising acquisitions and mergers, as well as expanding R&D efforts by biopharmaceutical companies to enhance various preventative vaccination kinds, have all had an impact on the industry's growth. For instance, Pfizer and Valneva have declared the completion of a portfolio of investments for the development and sale of prophylactic vaccines for infectious diseases in 2022.
The infectious disease segment is dominating the market with the largest revenue share over the forecast period.
On the basis of application, the global mRNA Therapeutics Market is segmented into Infectious Diseases, Oncology. Among these, the infectious disease segment is dominating the market with the largest revenue share of 99.8% over the forecast period. The rise in the usage of mRNA vaccines, outbreak of COVID 19 pandemic, and increasing number of candidates that are entering clinical trials for different communicable diseases are going to drive the market over the forecast period. On the other hand, the oncology segment is anticipated to expand exponentially over the forecast period.
As mentioned earlier, lung, rectum, colon, stomach, liver, and breast cancers are resulting the increase in the number of deaths across the world. So, increasing cases of chronic illness will increase the demand for mRNA vaccines therapies which are driving the market over the forecast period. Moreover, the lack of precision cancer therapy medicines is also pushing the government and the key market players to make investment in the research and development activities which will drive the segmental Growth.
End Use Insights
The hospitals and clinics segment accounted the largest revenue share of more than 61.2% over the forecast period.
On the basis of end use, the Global mRNA Therapeutics Market Size is segmented into hospitals and clinics, research organizations, and others. Among these, the hospitals and clinics segment accounted the largest revenue share of over 61.2% over the forecast period. The increasing use of vaccines and therapies for treating various chronic health ailments is inspiring for the personal pharmaceuticals in future. Apart from this, the rising number of patients visiting hospitals and clinics are also driving the market. Moreover, the increasing number of patients suffering from infectious diseases, influenza, cancer, and respiratory problems are anticipated to drive the market. For example, as per the NCBI report published in the year 2019, WHO estimated that up to 500,000 people die from influenza each year and about one billion people are sick, which is why hospitals and medical offices are Growing.
North America dominates the market with the largest market share over the forecast period.
Get more details on this report -
North America is dominating the market with more than 35.6% market share over the forecast period. The main reason behind the growth of this region is the availability of research funding, expansion of federal programs conducted for RNA based medications, as well as increasing number of clinical trials will boost the growth of the North American region. For instance, The National Institutes of Health (NIH), the Defence Department have strongly supported Graham and basic research which has helped in the fast development of COVID 19 vaccines.
Europe on the other hand had held second largest revenue share due to the increasing number of patients and rising awareness related to the genetic disorders. Apart from this, the presence of key market players present in European region and the increasing need for vaccines and therapies are boosting the regional growth. For instance, to assist the local delivery of mRNA vaccines and medicines, Moderna has established a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden.
The Asia-Pacific region is expanding at a promising CAGR due to the potential for gene silencing of these treatments the market for mRNA-based therapeutics. Yet, the market is still in its infancy in emerging nations like India and has had a lucrative growth rate during the course of the analysis period. Target specificity and selectivity of RNAi treatments, more focused product focus compared to platform technologies, and virtual drug development models that enable firms to lower the research cost are factors that will fuel the market expansion in the Asia-Pacific region.
Key Market Developments
- In November 2022, Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine is approved for use by Health Canada as a booster dose in people 18 years of age and older. Similar bivalent booster doses from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) with Omicron BA.1 or BA.4/5 variants were already approved by Health Canada in September and October of 2022, respectively.
- In October 2022, Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine is approved for use by Health Canada as a booster dose in people 18 years of age and older. Similar bivalent booster doses from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) with Omicron BA.1 or BA.4/5 variants were already approved by Health Canada in September and October of 2022, respectively.
List of Key Market Players
- Alnylam Pharmaceuticals
- BioNTech AG
- CureVac AG
- eTheRNA Immunotherapy
- Ethris GmbH
- Moderna Therapeutics
- Sangamon therapeutic Inc.
- Sanofi AG
- SCM Lifescience Co., Ltd
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis pharmaceuticals Inc.
- Nutcracker Therapeutics
- TIBA Biotech
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global mRNA Therapeutics market based on the below-mentioned segments:
mRNA Therapeutics Market, Application Analysis
- Infectious Diseases
mRNA Therapeutics Market, Type Analysis
- Prophylactic vaccines
- Therapeutic vaccines
- Therapeutic drugs
mRNA Therapeutics Market, End User Analysis
- Hospitals and clinics
- Research organizations
mRNA Therapeutics Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- What is the market size of mRNA therapy?
The global mRNA Therapeutics market is expected to grow from USD 33.60 Billion in 2021 to USD 38.15 Billion by 2030, at a CAGR of 2.2% during the forecast period 2022-2030.
- Who are the key market players of mRNA therapeutics market?
Some of the key market players of mRNA therapeutics market are Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, TIBA Biotech
- Which segment hold the largest market share?
Hospital and clinics segment hold the largest market share is going to continue its dominance.
- Which region is dominating the mRNA therapeutics market?
North America is dominating the mRNA therapeutics market with 35.6% market share.
Need help to buy this report?